At the end of June, the European Medicines Agency (short: EMA) approved the Bruton’s tyrosine kinase inhibitor Tolebrutinib (amsel.de reported immediately). The BTKi is approved for the indication of secondary progressive multiple sclerosis without relapses in the past two years. This makes a drug available for exactly that course of disease for which there were hardly any therapy options so far. Now, however, the EMA allows Tolebrutinib.
The approval of Tolebrutinib by the EMA
Prof. Mathias Mäurer has spoken several times in advance about Tolebrutinib and also about other BTKi. In this video interview he explicitly addresses the approval and its significance for people with secondary progressive MS, explains expected effects and possible side effects of the newcomer among the MS drugs. What does close liver value control mean in practice? Do you have to continue it for years?
According to the manufacturer, Tolebrutinib will be available in pharmacies during the year 2026. Besides Tolebrutinib, other active substances of the BTKi class are in the pipeline. Whether and when further BTKi could be approved is also a topic in this video:
This post was translated from German to English with the help of AI.
